EGFR and lung carcinoma: Results from this trial of cetuximab plus afatinib demonstrated that the combination therapy was effective in achieving tumor reduction (as assessed by CT scans using RECIST criteria) in patients with both Ex19Del and L858R EGFR-mutant lung cancer, in contrast to prior pre-clinical data42.